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Abstract 
Background: Peripheral artery disease (PAD) is an important global health problem and contributes to notable pro-
portion of morbidity and mortality. This particular manifestation of systemic atherosclerosis is largely under diagnosed 
and undertreated. For sustainable preventive strategies in a country, it is mandatory to identify country-specific risk 
factors. We intended to assess the risk factors of PAD among adults aged 40–74 years.
Methods: This case control study was conducted in 2012–2013 in Sri Lanka. Seventy-nine cases and 158 controls 
in the age group of 40–74 years were selected for the study in order to have case to control ratio 1:2. The criterion 
for selecting cases and control was based on Ankle brachial pressure index (ABPI). Cases were selected from those 
who had ABPI 0.85 or less (ABPI ≤0.85) in either lower limb. Controls were selected from those ABPI score between 
1.18 and 1.28 in both lower limbs. Only newly identified individuals with PAD were selected as cases. Controls were 
selected from the same geographical location and within the 5 year age group as cases.
Results: The history of diabetes mellitus more than 10 years (OR 5.8, 95% CI 2.2–14.2), history of dyslipidemia for 
more than 10 years (OR 4.9, 95% CI 2.1–16.2), history of hypertension for more than 10 years (OR 3.8, 95% CI 1.8–12.7) 
and smoking (OR 2.9, 95% CI 1.2–6.9), elevated HsCRP (OR 3.7, 95% CI 1.2–12.0) and hyperhomocysteinemia (OR 3.0, 
95% CI 1.1–8.1) were revealed as country specific significant risk factor of PAD.
Conclusions: Diabetes mellitus, hypertension, dyslipidemia, smoking as well as elevated homocysteine and HsCRP 
found as risk factors of PAD. Longer the duration or higher level exposure to these risk factors has increased the risk of 
PAD. These findings emphasis the need for routine screening of PAD among patients with the identified risk factors.
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Background
Peripheral artery disease (PAD) is an important global 
health problem and associated with considerably high 
morbidity and mortality [1]. It is a disease process 
resulting from obstruction of large peripheral arter-
ies, exclusive of the coronary and intracranial cerebro-
vascular system, commonly due to atherosclerosis [2]. 
This chronic slowly progressive disease is usually char-
acterized by occlusion of lower limb arteries ultimately 
causing acute or chronic limb ischemia. Although the 
association of PAD with higher risk of ischemic events 
has been identified, this particular manifestation of 
systemic atherosclerosis is largely under diagnosed and 
undertreated [2, 3]. The main systemic atherosclerotic 
vascular diseases, namely coronary artery disease (CAD), 
cerebrovascular disease (CVD) and PAD are leading 
causes of morbidity and mortality and all these diseases 
share the common pathophysiological process of athero-
thrombosis [4].
Advanced age, family history, smoking, diabetes mel-
litus, hypertension and dyslipidemia are commonly 
identified traditional cardiovascular risk factors of PAD 
[5–7]. A number of “nontraditional” risk factors for PAD 
have also been recognized including race and ethnicity, 
elevated inflammatory markers such as C-reactive pro-
tein, fibrinogen, leukocytes and interleukin-6, genetics, 
hypercoagulable states of altered blood levels of D-dimer, 
homocysteine, lipoprotein, and an abnormal waist-to-hip 
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ratio [8]. The risk-factor identification is important 
because PAD is associated with reduction in functional 
capacity and quality of life as well as increased cardiovas-
cular morbidity and mortality from myocardial infarction 
and CVA [9]. It is also associated with personal, social, 
and economic burden [3]. The risk factor modification 
plays an important role in managing patients with PAD 
in primary care setting and prevention of its complica-
tions [10]. Early diagnosis of PAD is essential to improve 
quality of life, to prevent further functional impairment, 
and to reduce mortality and morbidity from CAD and 
CVD. For sustainable preventive strategies in a country, 
it is mandatory to identify the prevalence of the disease 
and identifying country-specific modifiable risk factors. 
A recent study found the age and sex adjusted prevalence 
of PAD in Sri Lanka to be as 3.6% [11]. There are no stud-
ies on risk factors of PAD in Sri Lanka. This study was 
intended to identify the country specific risk factors of 
PAD which will help to address preventive measures of 
PAD in Sri Lanka.
Methods
Study population
This case control study was conducted in parallel to a 
cross sectional prevalence survey in the Gampaha dis-
trict in Sri Lanka in 2013. Gampaha is the second most 
populous district in Sri Lanka, and has a population of 
2 million. Cross sectional survey was conducted using 
a multistage probability proportionate to size sampling 
technique to recruit 2912 adults aged 40–74 years from 
104 clusters. Cluster size was 28 with equal number of 
males and females. Detailed methodology of this cross 
sectional survey has been described in previously pub-
lished paper [11]. Identification of cases and controls 
was based on ankle brachial pressure index (ABPI). The 
measurement of ABPI was performed according to the 
procedure described in American College of Cardiology 
and American Heart Association guidelines for the man-
agement of patients with peripheral arterial disease [6].
Assessment of ABPI was done using “Summit Vista ABI 
L 450’’ arterial doppler instrument. The ABPI was calcu-
lated up to 2 decimal places for each lower limb as the 
ratio of the highest systolic blood pressures at the ankle 
and the highest of the left and right brachial systolic pres-
sures. The cutoff level of ABPI to select cases and con-
trols was based on a study validating ABPI measurements 
for Sri Lankan population [12]. To ensure 100% specific-
ity and no false positives among cases, only newly identi-
fied individuals who had ABPI value 0.85 or less in either 
lower limb were selected as cases. There by, all those 
who were identified as cases were incident cases. Con-
trols were identified from those who had ABPI within the 
range of 1.18–1.28 in both lower limbs. Those who had 
undergone any type of surgery or procedure for PAD pre-
viously were excluded from the study.
Sample size was determined based on the formula for 
case control study [13]. Odds ratios and rate of exposure 
among controls were obtained from both local studies 
and studies done in other countries [6, 14–16]. A confi-
dence interval of 95% and a power of 80% were selected. 
Largest sample size was selected after applying reported 
odds ratios as the relative frequency of the exposure, 
assuring adequate precision and power [17]. To accom-
modate for low number of cases, case to control ratio 
was decided as 1:2, without compromising the power of 
the study [17, 18]. Thus, 79 cases and 158 controls were 
recruited for the study. Controls were selected from the 
same geographical location and within the 5  year age 
group as cases. It is well known that PAD is mainly an age 
related disease [19, 20]. Matching was done only for age 
variable. Thus, it allows all other selected variables to be 
assessed as potential risk factors of PAD.
Data collection
Both cases and controls were subjected to an interviewer 
administered questionnaire (IAQ). IAQ inquired on socio 
demographic factors such as age, religion, ethnicity, level 
of education and family income. Presence of selected 
non-communicable disease conditions such as diabetes 
mellitus, hypertension, dyslipidemia, coronary artery 
disease, cerebrovascular disease and PAD was obtained 
with duration of illness. All these information were self-
reported and verified by available clinical records or 
medicines. In addition, information on family history 
of selected non-communicable diseases; diabetes melli-
tus, hypertension, dyslipidemia, coronary artery disease, 
cerebrovascular disease and PAD and information on 
smoking, usage of alcohol, were also inquired. Smoking 
status was categorized as ever smokers, current smokers, 
and former smokers according to the classification of the 
Centers for Disease Control and Prevention in the United 
States [18]. Lifetime exposure to smoking was assessed 
by pack-year smoking values. Alcohol intake was cat-
egorized as abstainers, less frequent users and frequent 
users according to the definition of the National Insti-
tute on Alcohol Abuse and Alcoholism in United States 
[21]. In all participants generalized obesity was assessed 
using body mass index (BMI) and abdominal obesity was 
assessed using waist circumference (WC) and waist hip 
ratio (WHR). Body weight was measured in kilogram to 
the nearest 0.1  kg using a “Seca 876” electronic digital 
standing-on weighing scale. The standing body height 
measured in centimeter to the nearest 0.5  cm using a 
“Seca 213” stadiometer. The waist circumference and 
hip circumference measured in centimeters to the near-
est 0.2  cm using a “Seca 201” ergonomic circumference 
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measuring tape. Measurement of height, weight, waist 
circumference (WC) and hip circumference (HC) were 
carried out according to the guidelines given by anthro-
pometry procedures manual, Centres for Disease Control 
in United States [22]. The cut off values for generalized 
obesity and abdominal obesity was defined based on 
the guidelines given by the International Obesity Task 
Force-WHO for Asians [23], and report of WHO expert 
consultation on waist circumference and waist-hip ratio 
respectively [24].
Fasting plasma glucose, lipid profile, high sensitivity 
C reactive protein (HsCRP) and serum homocysteine 
was measured using standardized fully automated tech-
niques in an internationally accredited laboratory in a 
private hospital, Sri Lanka. The laboratory quality control 
measures included routine external and internal quality 
control procedures at regular intervals. The standard rea-
gents were used for biochemical analysis as per the man-
ufacturer recommendations. Reagents packs used in the 
study were supplied by Siemens healthcare Diagnostics 
Inc, Newark, USA and Abbott Laboratories, Germany 
which were pre-validated and approved for respective 
analyzers.
Cutoff values for DM and dyslipidemia was based on 
guidelines given by World Health Organization Depart-
ment of Non-communicable Disease Surveillance and 
Adult Treatment Panel III (ATP III) National cholesterol 
education programme [25]. The serum HsCRP level more 
than 3 mg/L was considered as elevated HsCRP and the 
serum homocysteine level more than 15 mol/L was con-
sidered as elevated homocysteine or hyperhomocysteine-
mia [26, 27].
The Ethics Review Committee of the Faculty of Medi-
cine, University of Colombo granted the approval for the 
study. Informed written consent was obtained from all 
patients prior to participation.
Statistical analysis
Analysis was done using Statistical Package for Social 
Science (SPSS). Bivariate analysis for the PAD and non-
PAD by selected characteristics of respondents was done 
and differences between groups were analyzed with Pear-
son’s Chi square tests. Unconditional Multivariate logis-
tic regression (MLR) analysis was performed to identify 
the independent risk of each variable with PAD, adjusted 
by confounders. The model produced logistic regres-
sion co-efficient (β co-efficient), which estimated the 
adjusted OR for each of the independent variable in the 
MLR. The dependent variable used in the MLR analysis 
was the presence (cases) or absence (controls) of PAD. 
The independent variables used in the MLR analysis were 
based on the variables that showed a statistical significant 
association with PAD at a significance level of 0.05 in the 
bivariate analysis (unadjusted by confounding variables). 
Out of these variables, some variables were excluded 
from the MLR analysis if they had a limited number of 
subjects in one cell or if they showed a high inter-cor-
relation with other variables. The independent factors 
included in the model were selected socio-demographic 
measures, presence of long term medical conditions such 
as DM, hypertension, dyslipidemia, smoking and alcohol 
usage, BMI, WC, WHR, presence of hyperhomocysteine-
mia and high level of HsCRP. Statistical significance was 
set at p < 0.05. MLR analysis was performed for identified 
dependent and independent variables by carrying out 
backward stepwise binominal LR method. The Probabil-
ity for this method was fixed for entry at 0.05 and removal 
at 0.1 significance level. The model that showed the best 
goodness-of-fit in the MLR analysis was selected as the 
best model. Goodness of fit of the MLR was assessed by 
the overall percentage of the predictions that were cor-
rectly classified by observed outcomes. Goodness of fit 
of the MLR model was assessed using Omnibus tests, 
Hosmer and Lemeshow tests and Cox and Snell R square 
(R2) and Negelkerke R2 tests. The Omnibus tests of model 
coefficients were used to test how well the model per-
forms or the capability of all predictors in the model 
jointly to predict the dependent variable. A well-fitting 
model is significant at the level of 0.05 or below, indicat-
ing that the final model fits the data adequately. Hosmer 
and Lemeshow test was also used as a goodness of fit test 
and good fit is significant at the level of 0.05 or more. Cox 
and Snell R2 and Negelkerke R2 values were also used to 
provide an indication of the amount of variation in the 
dependent variable explained by the model. The variables 
retained in the MLR model were considered as independ-
ent risk factors adjusted for the confounders for predic-
tion of development of PAD.
Results
All the selected cases (79) and controls (158) participated 
in the study making the response rate 100%. The mean 
age of cases was 64.3 years (SD 7.6) and median age was 
65 years (IQR 60–70 years). The mean and median ages 
of controls were 64.3  years (SD 7.7) and 66  years (IQR 
60–71 years) respectively.
Comparison of socio-demographic characteristics 
among cases and controls is shown in Table 1. Compared 
to controls a significantly higher proportion of cases 
had a history of diabetes mellitus (71.6%), hypertension 
(78.4%) and dyslipidemia (73.9%). When considering the 
duration of the disease, a significantly higher proportion 
of cases found to have history of 5 years or more for dia-
betes mellitus, hypertension, or dyslipidemia than con-
trols (p < 0.01) (Table 2). Current smokers among cases 
(20.2%) were significantly higher than controls (8.2%) 
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(p  <  0.01). Further, the proportion of those exposed to 
10 or more pack years among cases (31.6%) was also sig-
nificantly higher than the proportion of controls (6.9%, 
p < 0.01) (Table 3).
Anthropometric measurements were not found sig-
nificantly different between cases and controls (Table 4). 
Two serum biomarkers were assessed to determine the 
risk of PAD. Based on distribution of serum values of 
HsCRP and homocysteine in controls, both cases and 
controls were categorized into quartiles. Homocysteine 
and HsCRP levels among PAD cases was significantly 
higher than controls (p < 0.001) and elevated blood levels 
of HsCRP (>3 mg/dl) and homocysteine (>15 mg/dl) than 
controls (p < 0.05) (Table 5).
The statistical significance of the overall model as well 
as the significance of individual steps of the model was 
assessed by Omnibus test. In Omnibus tests of model 
coefficients, the Chi square value was 159.3. This value 
was highly significant (p < 0.001). Hosmer and Lemeshow 
test also supported the model, where Chi square value 
was 8.9 with 8 degrees of freedom (p = 0.35). Since poor 
fit is indicated by significance value <0.05, significance 
value 0.35 in this test support for the model. In the final 
model Cox and Snell R2 was 0.680 and the Nagelkerke’s 
R2 was 0.780. This means that the final model explains 
68.0–78.0% of the variance in PAD in the sample. In 
logistic regression analysis the history of diabetes melli-
tus more than 10  years (OR 5.8, 95% CI 2.2–14.2), his-
tory of dyslipidemia for more than 10 years (OR 4.9, 95% 
CI 2.1–16.2), history hypertension for more than 10 years 
(OR 3.8, 95% CI 1.8–12.7) and ever smoking (OR 2.9, 
95% CI 1.2–6.9) were found as risk factors. In addition, 
elevated HsCRP (OR 3.7, 95% CI 1.2–12.0) and hyper-
homocysteinemia (OR 3.0, 95% CI 1.1–8.1) were also 
revealed as significant risk factor of PAD after controlling 
for other confounding factors (Table 6).
Discussion
This is the first case control study on PAD in Sri Lanka. 
This study was able to identify country specific risk fac-
tors of PAD which will help to address preventive meas-
ures of PAD in Sri Lanka. Use of validated ABPI cut off 
values in selecting cases and controls minimized any 
misclassification in our study. Selecting non diseased 
Table 1 Bivariate analysis of  demographic and  socioeco-
nomic characteristics
* Not analyzed as age was matched for 5 year age groups





No % No. %
Age group (years) *
45 05 6.3 10 6.3
50 07 8.9 14 8.9
55 07 8.9 14 8.9
60 16 20.3 32 20.2
65 17 21.5 34 21.5
70–74 27 34.2 54 34.2
Sex 0.195
Male 39 49.4 92 58.2
Female 40 50.6 66 41.8
Sector of residence  0.401
Rural 56 70.9 120 75.9
Urban 23 29.1 38 24.1
Ethnicity 0.802
Sinhala 78 98.7 157 99.4
Tamil 01 1.3 01 0.6
Level of education 0.225
Up to Grade 10 37 46.8 61 38.6
GCE O/L completed and above 42 53.2 97 61.4
Monthly household income Rs 0.263
≥30,000 29 36.7 70 44.3
<30,000 50 63.3 88 55.7
Table 2 Bivariate analysis of history of selected diseases
CAD coronary artery disease; CVA cerebrovascular disease; PAD peripheral 
arterial disease





No % No %
Diabetes mellitus by history
No history 22 27.9 109 69.0 <0.0001
<5 years 01 1.3 07 04.4
5–10 years 11 13.9 10 6.3
≥10 years 45 56.9 32 20.3
Hypertension by history
No history 18 22.8 86 54.4 <0.0001
≤5 years 04 5.1 27 17.1
5–10 years 12 15.2 12 7.6
≥10 years 45 56.9 33 20.9
Dyslipidemia by history
No history 22 27.9 95 60.2 <0.0001
<5 years 04 5.0 22 13.9
5–10 years 20 25.3 17 10.7
≥10 years 33 41.8 24 15.2
Presence of family history
Diabetes mellitus Yes 29 36.7 46 29.1 0.235
Hypertension Yes 25 31.6 49 31.0 0.921
Dyslipidemia Yes 20 25.3 22 13.9 0.030
CAD Yes 11 13.9 12 7.5 0.120
CVA Yes 16 20.3 18 11.4 0.066
PAD Yes 01 1.3 03 1.9 0.858
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individuals as cases as well as selecting disease individu-
als as control leads to under estimation of the risk [28]. 
The cutoff levels of ABPI for selection of cases and con-
trols were based on the finding of a validation study of 
ABPI [12]. All the cases of our study were incident cases 
detected during the community based prevalence survey 
[11]. As latent period of PAD is long, modification of risk 
factors following diagnosis becomes a major drawback 
if prevalent cases were selected for a case control study. 
Hence, we were able to minimize differential recall of 
possible exposure to risk factors between cases and con-
trols in our study by only enrolling incident cases.
The final MLR model was able to predict 68–78% of the 
variance of PAD, indicating that over two-thirds of the 
variables determining PAD have been identified in our 
study. Thus, findings of this study are useful for health-
care providers to take preventive action to reduce the 
Table 3 Bivariate analysis of smoking and alcohol usage





No % No %
Never smoker 49 62.0 121 76.6 0.018
Current smoker 16 20.2 13 8.2
Former smoker 14 17.7 24 15.2
Type of smoking
Never smoker 49 62.0 121 76.6 0.080
Cigarette only 17 21.5 24 15.2
Cigarette and Beedi 07 8.8 09 5.7
Beedi only 6 7.6 04 2.5
Pack year smoking
<5 50 1.3 16 10.1 0.080
5 04 5.0 10 6.3
≥10 25 31.6 11 6.9
Alcohol usage
Abstainers 42 53.2 97 61.4 0.071
Less frequent users 12 15.2 21 13.3
Frequent users 25 31.6 40 25.3







No % No %
Generalized obesity
BMI<18.5 kg/m2 17 21.5 16 10.1 0.067
BMI 18.5–24.9 kg/m2 25 31.6 52 32.9
BMI ≥25 kg/m2 37 46.8 90 57.0
High Waist circumference 0.782
Yes 37 46.8 77 48.7
No 42 53.2 81 51.3
High Waist hip ratio 0.331
Yes 49 62.1 108 68.3
No 30 37.9 50 31.6
Table 5 Bivariate analysis of  high sensitivity C reactive 
protein and homocysteine





No % No %
High sensitivity CRP (HsCRP)
1st quartile 10 12.7 39 24.7 <0.001
2nd quartile 11 13.9 40 25.3
3rd quartile 12 15.2 40 25.3
4th quartile 46 58.2 39 24.7
Homocysteine
1st quartile 05 6.3 39 24.7 <0.001
2nd quartile 17 21.5 40 25.3
3rd quartile 21 26.6 40 25.3
4th quartile 36 45.6 39 24.7
Elevated Hs CRP (>3 mg/dl) <0.001
No 32 40.5 118 74.7
Yes 47 59.5 40 25.3
Hyperhomocysteinemia (>15 mg/dl) <0.001
No 22 27.8 80 50.6
Yes 57 72.2 78 49.4
Table 6 Parameter estimates and their significance—mul-
tivariate logistic regression analysis
Variable Category OR 95% CI for OR
Lower Upper
Diabetes mellitus by history No 1.0
5–9 years 1.5 0.2 9.0
≥10 years 5.8 2.2 14.2
Dyslipidemia by history No 1.0
5–9 years 2.6 0.7 8.8
≥10 years 4.9 2.1 16.2
Hypertension by history No 1.0
5–9 years 2.6 0.7 8.8
≥10 years 3.8 1.8 12.7
Smoking status Never smoker 1.0
Ever smoker 2.9 1.2 6.9
ElevatedHsCRP No (≤3 mg/l) 1.0
Yes (>3 mg/ml) 3.7 1.2 12.0
Hyperhomocysteinemia No (≤15 mg/ml) 1.0
Yes (>15 mg/ml) 3.0 1.1 8.1
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burden of disease in the country by early identification of 
risk factors. In the multivariate analysis, presence of his-
tory of diabetes mellitus, hypertension or dyslipidemia 
for 10 or more years, smoking, elevated CRP (>3  mg/
dl), hyperhomocysteinemia (>15  mg/dl) were found to 
be independent risk factors for PAD among Sri Lankan 
adults. There are number of supportive research find-
ings similar to our study. American Diabetes Association 
reported diabetes mellitus as the strongest risk factor of 
PAD [29]. National Health and Nutrition Examination 
Survey found Odds ratio (OR) of 2.08 for presence of 
DM (95% CI 1.01–4.28) [30]. In the San Diego population 
study the OR of diabetes mellitus for PAD was reported 
as 6.9 (p < 0.001) [19]. Dyslipidemia also has been identi-
fied as a significant risk factor for PAD in many studies. 
Ridker et al. reported dyslipidemia as an independent risk 
factor (RR 3.0, 95% CI 1.5–6.1) [31]. National Health and 
Nutrition Examination Survey also found the OR for dys-
lipidemia as high as 1.7 (95% CI 1.01–2.74) [30]. A cross 
sectional study conducted in Finland by Korhonen et al.
(OR 2.3, 95% CI 1.56–6.58), Rotterdam follow up study 
(OR 1.32, 95% CI 1.07–1.64) and San Diego Population 
Study (RR 1.85, p = 0.01) have reported hypertension as 
a significant risk factor of PAD [19, 32, 33].
Most of the previous studies have assessed the risk for 
PAD only in relation to the presence or absence of diabetes 
mellitus, dyslipidemia and hypertension and not related 
to the duration of the illness. Although the exact time of 
onset of these conditions is difficult to estimate, at least the 
known duration of disease after detection provides impor-
tant information about development of PAD. Therefore, 
we assessed the risk of PAD according to the history of 
duration of diabetes mellitus, dyslipidemia and hyperten-
sion. Having diabetes mellitus, dyslipidemia or hyperten-
sion for 10 years or more duration was found as significant 
risk factors of PAD. Korhonen et  al. [32], reported that 
newly diagnosed pre-diabetes or diabetes per se is not 
associated with PAD, whereas long-lasting diabetes melli-
tus remains a well-established risk factor. In a prospective 
cohort study in USA, Joosten et al. [34] highlight that inci-
dence of PAD significantly increases with the duration of 
diabetes mellitus, dyslipidemia and hypertension.
We found that ever smoking as significant risk factor 
for PAD in the MLR analysis. Many studies have identi-
fied smoking as a potent risk factor of PAD with consist-
ent dose response relationship. A study carried out in 
Beijing, found both current smoking and former smok-
ing (OR 1.5, 95% CI 1.1–2.1) as a significant risk factor 
of PAD [35]. The San Diego Population Study has identi-
fied pack year smoking more than 20 (OR 1.6, p < 0.01) 
and Framingham offspring study-pack year smoking of 
10 years (OR 1.3, CI 1.2–1.4) as significant risk factors of 
PAD [19, 36]. A systematic review by Willigendael et al. 
found that the prevalence of PAD had increased by 2–3-
fold among current smokers compare to nonsmokers and 
a clear dose–response relationship [37]. In our study pack 
year smoking was not found as a significant risk factor 
in the final MLR model. No significant association was 
found between use of alcohol and PAD in our study. Sim-
ilar results have been reported in previous studies as well 
[33–36]. However, Strong heart study found that cur-
rent alcohol consumption is negatively associated with 
PAD (OR 0.26, p < 0.03) [38]. However, it was based on a 
minority population in USA. Therefore results of Fabsitz 
et al. study cannot be considered conclusive.
We assessed the association between blood levels of 
HsCRP and homocysteine with PAD. In the present 
study we found elevated HsCRP (>3  mg/L) and Hyper-
homocysteinemia (>15  mg/dl) to as significant risk fac-
tors of PAD. Many previous case control and follow up 
studies [31, 39, 40], have identified higher level of HsCRP 
as a significant risk factor of PAD. Garofolo et  al. in a 
cross sectional study in Brazil [41], found that the risk of 
homocysteinemia for PAD was significant (OR 1.5, 95% 
CI 1.02–2.25). Aronow and Ahnalso reported homocyst-
eine as a significant risk of for PAD (OR 1.12, p < 0.001) 
[42]. Systematic reviews carried out by Boushey et  al., 
[43] and Khandanpour et al., [44] also found homocyst-
eine as a significant risk factor of PAD (OR 4.3, 95% CI 
1.7–6.9) supporting our results.
Literature shows inconsistent results for sex as a risk 
factor of PAD. Bennett et  al. reported that males are at 
significant higher risk for PAD among migrant South 
Asians in UK (OR 2.81, 95% CI 1.31–6.0). In the same 
study they found sex was not a significant risk factor 
among black ethnicity the (OR 0.65, 95% CI 0.21–2.01) 
[45]. In contrary, Sigvant et al. found a higher prevalence 
of PAD among females [46]. Similar to our findings, many 
studies has reported non significant association between 
sex and PAD [19, 30]. Similarly, way inconsistent results 
have been reported by many studies for obesity as a risk 
factor of PAD. In our study BMI, HR and WHR were 
not found as significant risk factors of PAD. The Beijing 
study, reported that risk for PAD was 1.05 (95% CI 1.02–
1.08) for each 1 kg/m2- increment in BMI [35]. Lu et al. 
has found that WHR increases the risk of PAD in men 
(OR 4.68, 95% CI 2.1–10.3) and higher WC increases the 
risk of PAD in women (OR 2.94, 95% CI 1.01–8.8) [47]. 
Some studies have reported BMI as a protective factor 
for PAD [19, 48]. However, many others reported the 
association between obesity and PAD was not significant 
[30, 33, 36, 49–53]. It should also be noted that findings 
in studies conducted in different populations, particularly 
in minority groups or in diverse settings has shown slight 
differences. Thus, association of obesity and sex with 
PAD was inconclusive.
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Conclusion
These results demonstrate diabetes mellitus hyper-
tension or dyslipidemia as well as smoking as country 
specific risk of PAD. In addition, there is a high risk 
of PAD among persons with high level of homocystein 
and HsCRP. Longer the duration or higher level expo-
sure to these risk factors has increased the risk of PAD. 
These findings emphasis the need of routine screen-
ing of PAD among individuals with the identified risk 
factors.
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